In summary, this work shows for the first time that inhibition of STAT5B expression might be a promising targeting strategy to bypass the resistance of CML and AML cells to TKI or conventional chemotherapeutic agents. The gene discussed is STAT5B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.